DIAS Stock Overview
Engages in development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
DiaSorin S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €106.85 |
| 52 Week High | €111.95 |
| 52 Week Low | €82.84 |
| Beta | 0.19 |
| 11 Month Change | 4.29% |
| 3 Month Change | 4.60% |
| 1 Year Change | 21.04% |
| 33 Year Change | -42.43% |
| 5 Year Change | n/a |
| Change since IPO | -32.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| DIAS | AT Medical Equipment | AT Market | |
|---|---|---|---|
| 7D | 2.2% | 0.9% | -0.6% |
| 1Y | 21.0% | 11.7% | 2.5% |
Return vs Industry: DIAS exceeded the Austrian Medical Equipment industry which returned 11.7% over the past year.
Return vs Market: DIAS exceeded the Austrian Market which returned 2.5% over the past year.
Price Volatility
| DIAS volatility | |
|---|---|
| DIAS Average Weekly Movement | 3.5% |
| Medical Equipment Industry Average Movement | 6.0% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in AT Market | 6.6% |
| 10% least volatile stocks in AT Market | 1.8% |
Stable Share Price: DIAS has not had significant price volatility in the past 3 months compared to the Austrian market.
Volatility Over Time: DIAS's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1968 | 3,186 | Carlo Rosa | diasoringroup.com/en |
DiaSorin S.p.A. engages in development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIASON IQ, LIAISON XL, LIAISON XXL, and LIAISON XL LAS. It also offers molecular diagnostics platforms comprising of LIAISON NES, a new molecular platform to address the growing diagnostic decentralization trend; the ARIES and ARIES M1 systems; LIAISON MDX, a thermocycler with two consumable disc options; LIAISON MDX Plus; MAGPIX System; Luminex 100/200 System; VERIGENE System; and the LIAISON PLEX System.
DiaSorin S.p.A. Fundamentals Summary
| DIAS fundamental statistics | |
|---|---|
| Market cap | €5.73b |
| Earnings (TTM) | €188.85m |
| Revenue (TTM) | €1.18b |
30.3x
P/E Ratio4.9x
P/S RatioIs DIAS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DIAS income statement (TTM) | |
|---|---|
| Revenue | €1.18b |
| Cost of Revenue | €406.02m |
| Gross Profit | €772.19m |
| Other Expenses | €583.34m |
| Earnings | €188.85m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.54 |
| Gross Margin | 65.54% |
| Net Profit Margin | 16.03% |
| Debt/Equity Ratio | 42.6% |
How did DIAS perform over the long term?
See historical performance and comparison